Overview
Tesamorelin is a synthetic GHRH analog that is FDA-approved (as Egrifta) for the treatment of HIV-associated lipodystrophy (excess abdominal fat). It is one of the few peptides with full FDA approval and robust clinical trial data. It is increasingly used off-label for body composition optimization and anti-aging.
Mechanism of action
Tesamorelin is a modified GHRH(1-44) with a trans-3-hexenoic acid group attached to the tyrosine at position 1, which increases its potency and stability. It stimulates the pituitary gland to produce and release growth hormone in a pulsatile, physiological pattern. It specifically reduces visceral adipose tissue (VAT) without significantly affecting subcutaneous fat.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| visceral fat reduction | subcutaneous | 1–2 mg | daily | Inject in abdomen. FDA-approved dose is 2mg daily. Cycle length varies; clinical trials ran 26-52 weeks. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Phase III clinical trials (LIPO-010, LIPO-011) demonstrated significant reductions in trunk fat (-15.2%) and visceral adipose tissue in HIV patients. Also shown to reduce liver fat, improve cognitive function in older adults with mild cognitive impairment (2020 study), and reduce carotid intima-media thickness (cardiovascular marker). GH and IGF-1 increases are dose-dependent and clinically meaningful.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Tesamorelin for synergistic effects.
Legal status
FDA-approved as Egrifta for HIV-associated lipodystrophy. Available by prescription. Also available through compounding pharmacies for off-label use.
Where to get it
Prescription required
Tesamorelin is a prescription medication. Consult your healthcare provider or a licensed telehealth platform for access.